Exercise Matters Following Cancer

• by Julia Cipriano, MS, CMPP

• February 17, 2026

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

• by Kathryn Wighton

• July 10, 2026

• 2 min

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

• by Kathryn Wighton

• July 10, 2026

• 2 min

Is Accelerated Aging Tied to Early-Onset Carcinogenesis?

Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.

• by Andrea Surnit

• June 26, 2026

• 4 min